Skip to content
Biodatica
Start free

Xynomic Pharmaceuticals, Inc.

Phoenix, Arizona

OncologyantibodyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

4w agoTrial registeredJun 17, 2026Source filing (opens the source filing in a new tab)

Momentum

93no change

Momentum 93 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Mar 16, 2026

    Metastatic Prostate Cancer, Prostate Cancer · RECRUITING · sponsor: University of California, San Francisco · 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

    ClinicalTrials.gov · NCT07145177 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Jul 3, 2025

    Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Glioma, Malignant · RECRUITING · sponsor: Rahul Aggarwal · Imaging of Solid Tumors Using 18F-TRX

    ClinicalTrials.gov · NCT06942104 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Dec 15, 2023

    Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma · RECRUITING · sponsor: University of California, San Francisco · Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

    ClinicalTrials.gov · NCT05766371 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Jan 19, 2022

    Metastatic Castration-resistant Prostate Cancer, Prostate Cancer · ACTIVE_NOT_RECRUITING · sponsor: Rahul Aggarwal · FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

    ClinicalTrials.gov · NCT05011188 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Aug 10, 2021

    Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Solid Tumor, Adult, Solid Tumor, Metastatic Castration-resistant Prostate Cancer · TERMINATED · sponsor: Rahul Aggarwal · 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

    ClinicalTrials.gov · NCT04927663 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    May 10, 2019

    Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer · COMPLETED · sponsor: University of California, San Francisco · 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

    ClinicalTrials.gov · NCT03805594 (opens the source filing in a new tab)

  7. Trial

    PHASE2 registered

    Jan 29, 2019

    Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 · ACTIVE_NOT_RECRUITING · sponsor: National Cancer Institute (NCI) · Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

    ClinicalTrials.gov · NCT03284385 (opens the source filing in a new tab)

  8. Trial

    PHASE3 registered

    Jul 17, 2018

    Renal Cell Carcinoma · RECRUITING · sponsor: Xynomic Pharmaceuticals, Inc. · A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

    ClinicalTrials.gov · NCT03592472 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources